Compare HMN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | PHVS |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1991 | 2021 |
| Metric | HMN | PHVS |
|---|---|---|
| Price | $43.17 | $26.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $46.75 | $39.44 |
| AVG Volume (30 Days) | ★ 260.0K | 174.2K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ 57.26 | N/A |
| EPS | ★ 3.90 | N/A |
| Revenue | ★ $1,701,400,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $11.07 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $38.76 | $11.51 |
| 52 Week High | $48.33 | $29.80 |
| Indicator | HMN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 47.00 |
| Support Level | $42.03 | $24.92 |
| Resistance Level | $45.13 | $28.79 |
| Average True Range (ATR) | 1.09 | 1.46 |
| MACD | 0.23 | -0.22 |
| Stochastic Oscillator | 77.16 | 24.90 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.